{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:30:16Z","timestamp":1786480216721,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,12]]},"abstract":"\n Background<\/jats:title>\n \n Optimal induction for patients without pretransplant donor-specific antibodies (DSAs) is poorly defined. The goal of this study was to compare the incidence of\n de novo<\/jats:italic>\n DSA (dnDSA) and graft outcomes between induction therapies in patients with a negative virtual crossmatch (VXM).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective chart review was performed, identifying 782 patients with a negative VXM who underwent kidney transplantation at a single, high-volume institution between January 2013 and May 2017. Kaplan\u2013Meier analysis was used to assess the incidence of dnDSA and allograft survival between induction therapies in this group. dnDSA is defined as the development of new post-transplant DSA, at any MFI level.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Induction therapy included alemtuzumab (\n N<\/jats:italic>\n =87, 11%), basiliximab (\n N<\/jats:italic>\n =522, 67%), and anti-thymocyte globulin (ATG;\n N<\/jats:italic>\n =173, 22%). One-year graft survival was similar between groups (alemtuzumab, 100%; basiliximab, 98%; ATG, 99%). Incidence of acute rejection at 1 year was <2% and not different between the three groups. Alemtuzumab was associated with the highest incidence of dnDSA at 14%, compared with 5% and 8% in basiliximab and ATG groups, respectively, at 1 year (\n P<\/jats:italic>\n =0.009). In multivariate regression analyses, alemtuzumab retained its significant association with a dnDSA HR of 2.5 (95% CI, 1.51 to 4.25;\n P<\/jats:italic>\n =0.0004).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In summary, alemtuzumab was associated with a higher rate of dnDSA development in patients with a negative VXM; however, this finding was not associated with rejection or graft failure.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000122020","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T17:55:19Z","timestamp":1601574919000},"page":"1407-1418","source":"Crossref","is-referenced-by-count":7,"title":["Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients"],"prefix":"10.34067","volume":"1","author":[{"given":"Natalie M.","family":"Bath","sequence":"first","affiliation":[{"name":"Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjang","family":"Djamali","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh","family":"Parajuli","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Mandelbrot","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Leverson","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ellis","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian L.","family":"Descourouez","sequence":"additional","affiliation":[{"name":"Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Jorgenson","sequence":"additional","affiliation":[{"name":"Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Hager","sequence":"additional","affiliation":[{"name":"Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixon B.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Redfield","sequence":"additional","affiliation":[{"name":"Division of Transplant, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"issue":"Suppl 1","key":"B1-20230821","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ajt.14557","article-title":"OPTN\/SRTR 2016 annual data report: Kidney","volume":"18","author":"Hart","year":"2018","journal-title":"Am J Transplant"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1681\/ASN.2016070768","article-title":"Comparing outcomes between antibody induction therapies in kidney transplantation","volume":"28","author":"Koyawala","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181fecfcb","article-title":"Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: An analysis of United Network for organ sharing registry data","volume":"90","author":"Cai","year":"2010","journal-title":"Transplantation"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.TP.0000081042.67285.91","article-title":"A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients","volume":"76","author":"Goggins","year":"2003","journal-title":"Transplantation"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1600-6135.2003.00274.x","article-title":"Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients","volume":"4","author":"Bustami","year":"2004","journal-title":"Am J Transplant"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.4049\/jimmunol.1203261","article-title":"In kidney transplant patients, alemtuzumab but not basiliximab\/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development","volume":"191","author":"Todeschini","year":"2013","journal-title":"J Immunol"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/TP.0000000000000031","article-title":"Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients","volume":"97","author":"Brokhof","year":"2014","journal-title":"Transplantation"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1600-6143.2006.01711.x","article-title":"Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study","volume":"7","author":"Mao","year":"2007","journal-title":"Am J Transplant"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.TP.0000055833.65192.3B","article-title":"Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome","volume":"75","author":"Worthington","year":"2003","journal-title":"Transplantation"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/TP.0b013e31821c93bb","article-title":"Luminex-based desensitization protocols: The University of Wisconsin initial experience","volume":"92","author":"Niederhaus","year":"2011","journal-title":"Transplantation"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ki.2013.44","article-title":"Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients","volume":"83","author":"Djamali","year":"2013","journal-title":"Kidney Int"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/TP.0000000000002566","article-title":"Subclinical antibody\u2013mediated rejection after kidney transplantation: Treatment outcomes","volume":"103","author":"Parajuli","year":"2019","journal-title":"Transplantation"},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1097\/TXD.0000000000000746","article-title":"Rituximab and monitoring strategies for late antibody-mediated rejection after kidney transplantation","volume":"3","author":"Parajuli","year":"2017","journal-title":"Transplant Direct"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.trre.2013.07.001","article-title":"Interpretation of HLA single antigen bead assays","volume":"27","author":"Ellis","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1111\/ajt.14466","article-title":"Utility of protocol kidney biopsies for de novo donor-specific antibodies","volume":"17","author":"Parajuli","year":"2017","journal-title":"Am J Transplant"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/SLA.0000000000002025","article-title":"Frailty, length of stay, and mortality in kidney transplant recipients: A National registry and prospective cohort study","volume":"266","author":"McAdams-DeMarco","year":"2017","journal-title":"Ann Surg"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00007890-200112270-00008","article-title":"Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection","volume":"72","author":"Sollinger","year":"2001","journal-title":"Transplantation"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am J Transplant"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.TP.0000056635.59888.EF","article-title":"A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients","volume":"75","author":"Charpentier","year":"2003","journal-title":"Transplantation"},{"key":"B21-20230821","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.transproceed.2010.04.019","article-title":"A review of the evidence for use of thymoglobulin induction in renal transplantation","volume":"42","author":"Gaber","year":"2010","journal-title":"Transplant Proc"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1034\/j.1600-6143.2003.00120.x","article-title":"Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study","volume":"3","author":"Knechtle","year":"2003","journal-title":"Am J Transplant"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1111\/j.1600-6143.2005.01067.x","article-title":"Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction--long-term results","volume":"5","author":"Kaufman","year":"2005","journal-title":"Am J Transplant"},{"key":"B24-20230821","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"B25-20230821","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMc0805714","article-title":"Long-term results of rabbit antithymocyte globulin and basiliximab induction","volume":"359","author":"Brennan","year":"2008","journal-title":"N Engl J Med"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/tri.12043","article-title":"Selection of induction therapy in kidney transplantation","volume":"26","author":"Hardinger","year":"2013","journal-title":"Transpl Int"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/phar.1774","article-title":"Single-dose basiliximab induction in low-risk renal transplant recipients","volume":"36","author":"Cunningham","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B28-20230821","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1034\/j.1600-6143.2003.00135.x","article-title":"Humoral theory of transplantation","volume":"3","author":"Terasaki","year":"2003","journal-title":"Am J Transplant"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies","volume":"74","author":"Lee","year":"2002","journal-title":"Transplantation"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-6143.2006.01644.x","article-title":"Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival","volume":"7","author":"Terasaki","year":"2007","journal-title":"Am J Transplant"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: Mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B33-20230821","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrneurol.2013.2","article-title":"Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS","volume":"9","author":"Wiendl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"Thompson","year":"2010","journal-title":"J Clin Immunol"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000122020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:58:00Z","timestamp":1786478280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000122020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000122020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}